Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis

Table 3 Comparison of clinical factors in one month outcomes of the two groups of active ulcerative colitis patients receiving intravenous corticosteroids after oral corticosteroid therapy failure

	Good responders1(n = 44)	Poor responders2(n = 12)	P-value univariate
Gender (M/F)	24/20 (54.5/45.5)	8/4 (66.7/33.3)	0.956
Age (yr)	37 (11-78)	38 (29-59)	0.342
Disease duration (mo)
≤ 24	25 (56.8)	9 (75)	0.253
> 24	19 (43.2)	3 (3)
First attack of UC	18 (40.9)	8 (66.7)	0.113
Disease extent			0.943
Proctitis	3 (6.8)	1 (8.3)
Left-sided colitis	13 (29.5)	4 (33.3)
Extensive colitis	28 (63.6)	7 (58.3)
Disease activity
Full Mayo score (< 9/≥ 9)	23/19 (54.8/45.2)	4/5 (44.4/55.6)	0.574
Partial Mayo score (< 6/≥ 6)	12/32 (27.3/72.7)	2/10 (16.7/83.3)	0.452
Initial prednisolone dose (mg)			0.429
≥ 30 and < 40	24 (54.5)	5 (41.7)
≥ 40	20 (45.5)	7 (58.3)
Duration of oral corticosteroid use (d)
≤ 14	26 (59.1)	7 (58.3)	0.962
> 14	18 (40.9)	5 (41.7)
Concomitant medications			0.212
Salicylates	33 (75)	11 (91.7)
Azathioprine	11 (25)	1 (8.3)
CRP (mg/dL)
≤ 8	28 (63.6)	9 (75)	0.461
> 8	16 (36.4)	3 (25)
ESR (mm/h)	40.7 (3-120)	37.2 (12-83)	0.464
Hemoglobin (mg/dL)
≤ 11	15 (34.1)	3 (25)	0.550
> 11	29 (65.9)	9 (75)
Albumin (mg/dL)	3.6 (2.3-5.0)	3.45 (2.6-4.8)	0.295

¹Good responders included patients with prolonged response that maintained complete remission or partial remission after completion of corticosteroid therapy;

²Poor responders included patients with steroid dependence and non-response. M/F: Male/female; UC: Ulcerative colitis; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate.